We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00413751
Recruitment Status : Completed
First Posted : December 20, 2006
Last Update Posted : December 20, 2006
Information provided by:
Walter Reed Army Medical Center

Brief Summary:
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Condition or disease Intervention/treatment
Healthy Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Type : Observational
Estimated Enrollment : 20 participants
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Care
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

  • Patients not meeting above stated age criteria
  • Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
  • History of serious ocular, neurological, cardiovascular disease
  • History of severe systemic disease
  • History of arrhythmias or high blood pressure
  • Patients currently taking any type of ocular or systemic medications except multivitamins.
  • Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00413751

United States, District of Columbia
Walter Reed Army Medical Center
Washington, District of Columbia, United States, 20307
Sponsors and Collaborators
Walter Reed Army Medical Center
Principal Investigator: KRAIG S. BOWER, MD Walter Reed Army Medical Center

ClinicalTrials.gov Identifier: NCT00413751     History of Changes
Other Study ID Numbers: WRAMC WU #03-23004
First Posted: December 20, 2006    Key Record Dates
Last Update Posted: December 20, 2006
Last Verified: December 2006

Keywords provided by Walter Reed Army Medical Center:
Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia

Additional relevant MeSH terms:
Pharmaceutical Solutions
Ophthalmic Solutions
Brimonidine Tartrate
Antihypertensive Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs